Lack of retinal toxicity of the anti-CMV drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC)

D.R. Dolnack; D. Munguai; G Bergeron-Lynn; Clayton A. Wiley; De Clercq Erik; Claude Boscher; James D. Connor; W.R. Freeman

doi:10.1016/0166-3542(91)90287-2

Back

Discussion(0)

No comments yet. Be the first to comment.

Related publications

Article1992

Lack of retinal toxicity of the anticytomegalovirus drug (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl) cytosine.

Douglas Dolnak, D Munguia, Clayton A. Wiley, De Clercq Erik, G Bergeron-Lynn, Claude Boscher, James D. Connor, Charles H. Sherwood, Edmund V. Capparelli, Roksana Armani

Article1991

Particular characteristics of the anti-human cytomegalovirus activity of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC) in vitro

Johan Neyts, Robert Snoeck, Jan Balzarini, De Clercq Erik

Article1991

Efficacy of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine [HPMPC] against intraperitoneal and intracerebral murine cytomegalovirus infections

Johan Neyts, Jan Balzarini, De Clercq Erik

Article1994

(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC): successful treatment of a patient with disseminated esophageal and hypopharyngeal papillomatosis

Robert Snoeck, Eric Van Cutsem, Marc Van Ranst, Paul Rutgeerts, Ghislain Opdenakker, De Clercq Erik

Article1995

(S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC): A new approach for the treatment of human papillomavirus (HPV-induced tumors

Robert Snoeck, Graciela Andreï, Marc Van Ranst, Ghislain Opdenakker, De Clercq Erik